Non-invasive shockwave therapy to reduce penile curvature and scar tissue — doctor-led, fully confidential
Book a Confidential ConsultationPeyronie's disease is a condition where fibrous scar tissue (plaque) forms inside the penis, causing curved, painful erections. It can significantly affect sexual function and quality of life.
Focal shockwave therapy targets these plaques with acoustic sound waves, breaking down scar tissue, improving blood flow, reducing pain and gradually reducing curvature — all without surgery.
Shockwave therapy offers an effective alternative to surgery, breaking down fibrous plaques using acoustic sound waves with no incisions, no anaesthesia, and no recovery time.
Consistent treatment sessions help soften plaques and reduce the degree of penile curvature, improving function and comfort for most patients.
All consultations are completely private. We understand the sensitive nature of this condition and handle every case with full discretion and professionalism.
Low-intensity extracorporeal shockwave therapy (Li-ESWT) for Peyronie's disease is supported by published randomised controlled trial evidence and incorporated into major urological guidelines.
Multiple clinical studies have examined the application of Li-ESWT in men with Peyronie's disease. A landmark randomised controlled trial by Palmieri et al. (2012, Journal of Urology) demonstrated statistically significant reductions in penile pain and improvements in erectile function in treated patients compared to sham controls. Subsequent studies confirmed pain reduction as a robust and reproducible outcome, with approximately 70–80% of patients in the active treatment phase reporting meaningful improvement in pain scores following a complete course of focal shockwave therapy.
The biological mechanism underpinning these results is well characterised. Acoustic energy delivered to fibrous plaque tissue activates mechanotransduction pathways that upregulate matrix metalloproteinases (MMPs) — enzymes that directly degrade the abnormal Type I collagen composing the Peyronie's plaque. Simultaneously, Li-ESWT suppresses transforming growth factor-beta 1 (TGF-β1), the principal cytokine responsible for driving ongoing fibrosis within the tunica albuginea. This dual action — breaking down existing scar tissue while interrupting the fibrotic cascade — distinguishes shockwave from all oral and topical Peyronie's treatments, none of which reach the fibrous plaque directly.
The European Association of Urology (EAU) Guidelines on Male Sexual Dysfunction acknowledge Li-ESWT as an evidence-based option for reducing penile pain in the active (inflammatory) phase of Peyronie's disease. The guidelines note that the treatment is well tolerated, carries a low adverse event profile, and is appropriate to offer before considering surgical correction. At Shockwave Revibe Clinic, Dr Bahl uses the EMS Dolorclast Focal system — the same technology class used in the published trials — to deliver treatment at the precise depth and energy density required to reach the plaque within the tunica albuginea.
It is important to distinguish focal from radial shockwave for this indication. The tunica albuginea and its associated plaques lie deep within penile tissue — beyond the effective treatment depth of surface-dispersing radial devices. Focal shockwave delivers concentrated energy directly at the plaque, not diffusely around it. This anatomical precision is what the published evidence is based on, and why Dr Bahl uses focal — not radial — technology at every session.
Understanding the cause and phase of your condition allows Dr Bahl to target treatment precisely and set realistic, evidence-based expectations for your recovery.
Peyronie's disease most commonly develops following penile micro-trauma — often during sexual intercourse — that triggers an abnormal healing response in which fibrous scar tissue replaces healthy tunica albuginea. The following factors significantly increase risk:
Peyronie's disease affects an estimated 3–9% of adult men, though prevalence is likely underreported due to the sensitive nature of the condition. In all cases, the underlying process is the same: abnormal fibroblast activity within the tunica albuginea produces a fibrous, inelastic plaque that restricts normal penile expansion during erection.
Peyronie's disease progresses through two distinct phases that determine which treatment approaches are most appropriate:
New plaque is actively forming. Pain during erection is common and often the primary complaint. The degree of curvature may be changing month to month. This phase responds most reliably to Li-ESWT, as shockwave can interrupt the fibrotic process before plaques become fully calcified. Early treatment in this phase offers the best opportunity to limit permanent curvature development and reduce the ultimate plaque burden.
Plaque formation has stabilised and curvature is no longer progressing. Pain at erection typically resolves, though mechanical curvature, penile shortening, and associated erectile dysfunction remain. Focal shockwave in this phase targets plaque softening, improved penile blood flow, and co-existing vasculogenic erectile dysfunction — particularly valuable when surgical correction is not desired or where the patient wishes to exhaust non-invasive options first.
Oral medications, intralesional injections, and surgery each carry significant limitations. Here is how focal shockwave therapy compares on the factors that matter most to patients.
Many patients arrive at Shockwave Revibe Clinic having already tried oral medications with little benefit. Focal shockwave therapy is the logical next step before considering invasive intervention — and for many patients, it is the definitive non-surgical treatment. We also offer PRP Shot therapy as a complementary treatment that can be combined with shockwave for enhanced outcomes in appropriate cases.
Dr Bahl brings 30 years of medical experience to every consultation. As a Urology specialist, he understands the physical and emotional impact of Peyronie's disease and provides sensitive, evidence-based care in a completely private setting.
Yes. Focal shockwave therapy delivers targeted acoustic energy directly to fibrous plaques within the tunica albuginea — the structure responsible for penile curvature. This activates matrix metalloproteinases (MMPs) that degrade the abnormal Type I collagen composing the plaque, while simultaneously suppressing TGF-β1, the cytokine that drives continued fibrosis. The result is progressive plaque softening, reduction in penile pain during erection, and — in many patients — a gradual reduction in curvature over the treatment course. The European Association of Urology guidelines acknowledge Li-ESWT as an evidence-based option for pain management in the active phase of Peyronie's disease.
A standard course of focal shockwave therapy for Peyronie's disease is 6 to 12 sessions, depending on the phase and severity of your condition. Patients in the active inflammatory phase often require a full 12-session course to adequately interrupt plaque development, while those in the stable phase may respond well to 6 sessions targeting plaque softening and co-existing erectile dysfunction. Dr Bahl conducts a thorough clinical assessment at your initial consultation to determine the appropriate course length, and reassesses your progress at each appointment to adapt the plan as needed.
No. Focal shockwave therapy for Peyronie's disease is generally well tolerated without any anaesthetic. Patients typically describe the sensation as a firm tapping or mild vibration over the plaque area — discomfort is minimal and manageable throughout each session. Dr Bahl adjusts energy settings in real time to your comfort and response. Some patients experience mild post-treatment sensitivity in the treated area for 24 hours following a session, which is normal and resolves without intervention. You can return to normal activities, including work, immediately after each appointment.
Most patients notice a reduction in penile pain during erection from the second or third session onwards, as this is the outcome most responsive to early shockwave intervention. Progressive plaque softening and any reduction in curvature develop more gradually — typically becoming apparent over the full course of treatment and continuing for six to eight weeks afterwards, as collagen remodelling is an ongoing biological process. The degree of curvature improvement varies between patients and depends on plaque maturity, phase of disease, and individual healing response. Patients with early, active-phase Peyronie's disease typically see the greatest overall improvement from a complete treatment course.
Pricing is confirmed at your initial private consultation at our Notting Hill Gate clinic. The total cost depends on the number of sessions recommended following Dr Bahl's clinical assessment, which takes into account the phase and severity of your condition. Treatment is not available on the NHS, but some private health insurance policies may provide partial or full cover for Peyronie's disease treatment — we recommend checking with your insurer directly. Our clinic operates a fully confidential service with no external signage or identifiable correspondence. Please call 0203 0040 564 to discuss fees before booking.
Yes. At Shockwave Revibe Clinic, we offer Platelet-Rich Plasma (PRP) therapy as a complementary treatment to focal shockwave for selected Peyronie's disease patients. PRP is derived from your own blood and delivered to the plaque area, where concentrated growth factors — including PDGF, TGF-β, and VEGF — stimulate tissue remodelling and enhance the biological repair response initiated by shockwave. The combination is particularly considered for patients with well-established plaques seeking maximum non-surgical benefit, or those with co-existing erectile dysfunction that would benefit from the vascular regeneration effects of both treatments. Dr Bahl will advise whether combined therapy is appropriate for your individual case at consultation.
Yes. Shockwave Revibe Clinic is located at 22 Notting Hill Gate, London W11 3JE — directly at Notting Hill Gate Underground station (Central and Circle/District lines), making it easily accessible from across London. We regularly see patients from Kensington, Chelsea, Bayswater, Holland Park, Shepherd's Bush, Marylebone, Hammersmith, and across Greater London. We also see patients travelling from outside London who require specialist doctor-led focal shockwave therapy for Peyronie's disease in a fully confidential setting. If you have questions about accessibility or want to confirm appointment availability, please call us on 0203 0040 564.
Shockwave therapy to restore natural erectile function without drugs.
Platelet-rich plasma therapy to support penile tissue regeneration.
Shockwave therapy for tendon and soft tissue conditions.
Evidence-based articles on Peyronie's disease and men's health from our clinical team.
Clinical trial results on reducing penile curvature and plaque with non-invasive shockwave treatment.
Read article →Why drug-free shockwave therapy tackles the root cause of erectile dysfunction rather than masking symptoms.
Read article →Weekend appointments available. Doctor-led, fully private care at 22 Notting Hill Gate, London W11.
By booking an appointment you agree to our Privacy Policy
Book TodayShare your experience — your review helps others find our clinic.
